• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Stentys raises $13.9m to fund Euro expansion

Stentys raises $13.9m to fund Euro expansion

March 7, 2016 By Fink Densford

StentysStentys SA (EPA:STNT) said last week it raised $13.9 million through the sale of 5.6 million new shares to support its development and expansion.

The company said it will use the funds to expand in “European centers” by extending its distributor network and by obtaining regulatory approval in countries outside the CE Mark system. Stentys said its 1st targets will be Russia and India, with plans to expand into Brazil, China, Korea and Japan.

“We are delighted by the follow on from our shareholders to this capital increase, despite volatile financial markets. I would like to thank them for their support. This fund raising is building solid financial foundations for Stentys and allows the company to continue its growth strategy, in France and worldwide,” CEO Gonzague Issenmann said in prepared remarks.

Stentys said it also intends to “strengthen its position” in France with the newly raised cash, as well as funding 2 clinical studies that aim to obtain reimbursement clearance for its Xposition S.

The 1st study, titled Gain, will compare Xposition S to a conventional drug-eluting stent that already has reimbursement clearance in France. The study is slated to enroll 300 patients from 30 centers, the company said. Endpoints are set at artery diameter narrowing at 9 months as measured by angiography, and major adverse cardiac events.

The 2nd study, named Win, will compliment the Gain study to examine the safety and performance of the Xposition S stent in clinical practice. The company hopes to enroll 760 patients across 30 sites with a 12 month follow-up.

A separate study is planned to examine the efficacy of the Xposition S in treating Left Main lesions, slated to enroll 20 patients across 20 centers.

Last month, Stentys touted the results of its Apposition IV trial comparing the company’s Stentys self-apposing sirolimus-eluting coronary stent to Medtronic‘s (NYSE:MDT) Resolute stent in patients with ST-segment elevation myocardial infarction.

Results from the study were published in the journal Euro Intervention.

Filed Under: Business/Financial News, Stents Tagged With: Stentys

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy